Income Statement Presentation 2023
Changes to income statement presentation (2)
Revised, prior to Group allocation changes
Restated
Roche
Core basis
CHFM
30 June
2022
31 Dec
2022
Reclassifications
FY 2022 [HY 2022]
Core basis
CHFM
30 June
2022
31 Dec
2022
Sales
32,295
63,281
Sales
32,295
63,281
Royalties & Other Operating Income
1,605 2,533
660m
[319m]
Other Revenue
1,605
2,533
Cost of Sales
Research & Development
(9,305) (18,075)
1
Cost of Sales
(8,986)
(17,415)
(6,628) (14,053)
Research & Development
(6,245)
(13,255)
Selling, General & Administration
(5,714) (12,309)
798m
[383m]
Selling, General & Administration
(6,416)
(13,767)
Other Operating Income (Expense)
415
796
1,458m
[702m]
Core Operating Profit
12,668
22,173
Other Operating Income (Expense)
Core Operating Profit
415
796
12,668
22,173
① Cost of Sales: Reclassification of globally managed informatics, human resources and finance to SG&A.
2 Research & Development: Reclassification of globally managed informatics, human resources and finance to SG&A.
72
2View entire presentation